Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension
2007

Cost Analysis of Glaucoma Medications

publication Evidence: moderate

Author Information

Author(s): Frenkel Ronald EP, Frenkel Max, Toler Allison

Primary Institution: Bascom Palmer Eye Institute, University of Miami School of Medicine

Hypothesis

To determine the monthly cost and cost effectiveness of prostaglandin/prostamide therapy for lowering intraocular pressure in patients with glaucoma.

Conclusion

Bimatoprost 0.03% had the lowest monthly and annual costs and the greatest cost effectiveness for lowering IOP compared with latanoprost 0.005% and travoprost 0.004%.

Supporting Evidence

  • Bimatoprost 0.03% had the highest number of drops per bottle.
  • Bimatoprost 0.03% was found to be more cost effective than latanoprost and travoprost.
  • Prices for the medications increased significantly from 2001 to 2005.

Takeaway

This study looked at how much different eye drops for glaucoma cost and which one works best for lowering eye pressure. Bimatoprost is the cheapest and works the best.

Methodology

The study evaluated the costs and effectiveness of three glaucoma medications by analyzing drop counts, retail prices, and IOP reduction data.

Potential Biases

Potential bias in pharmacy selection and variability in retail costs.

Limitations

The study was limited by the number of bottles counted and the small number of pharmacies surveyed.

Participant Demographics

Patients with glaucoma or ocular hypertension.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2415-7-16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication